CN102172358A - Timicosin compound preparation and preparation method and use thereof - Google Patents
Timicosin compound preparation and preparation method and use thereof Download PDFInfo
- Publication number
- CN102172358A CN102172358A CN2011100663792A CN201110066379A CN102172358A CN 102172358 A CN102172358 A CN 102172358A CN 2011100663792 A CN2011100663792 A CN 2011100663792A CN 201110066379 A CN201110066379 A CN 201110066379A CN 102172358 A CN102172358 A CN 102172358A
- Authority
- CN
- China
- Prior art keywords
- tilmicosin
- compound preparation
- timicosin
- pidotimod
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Timicosin compound preparation and a preparation method and use thereof, which relate to the field of livestock breeding. The Timicosin compound preparation comprises the following components: Timicosin and Pidotimod. The invention also provides the preparation method and use of the Timicosin compound preparation. The Timicosin compound preparation provided by the invention is simple in composition and high in safety; and the Timicosin and Pidotimod in the compound preparation can produce a synergic effect in body, so that the Timicosin, at a lower use concentration, can reduce the number of the blue ear disease viruses in the bodies of newly borne piglets by inhibiting the blue ear disease virus content in the body of sows and thus improves the immunity in the bodies of the piglets and the indexes of the productivity of the piglets and reduce breeding benefit. The Timicosin compound preparation prepared by the invention can be used for breeding sows in a pregnant or lactation period. In addition, the preparation method provided by the invention is simple, and the prepared Timicosin compound preparation is stable.
Description
Technical field
The present invention relates to the livestock culture field, relate in particular to a kind of tilmicosin compound preparation and its production and application.
Background technology
Tilmicosin belongs to big lopps esters medicine, be the special-purpose antibiotic of poultry, its has a broad antifungal spectrum, have very strong antibacterial activity and unique characteristics of pharmacokinetics, that body absorbs is fast, apparent volume of distribution is big, selective enrichment function etc., in characteristics such as lung tissue and Ruzhong drug level height, long half times, all gram positive bacterias and part gram negative bacteria, mycoplasma, spirillum etc. all there are inhibitory action, have the activity stronger than tylosin.Simultaneously, tilmicosin can effectively be controlled reproductive and respiratory syndrome virus (PRRSV) and infect pig breeding dysfunction and the immunosuppressant that is caused, thereby regulate macrophage function and play antivirus action, can avoid PRRSV that the body performance in piglet whole growth cycle is caused adverse effect.But when tilmicosin used separately, the course of treatment was longer, large usage quantity (if sneak in the feedstuff and use, its concentration should more than 400g/ ton feedstuff), and the cost height is unfavorable for applying in the actual production.
Pidotimod is a kind of oral immunity promoter, can promote the activate the phagocytic capacity of macrophage and neutrophilic granulocyte, though do not have directly antibiotic and antiviral activity, by the promotion of body's immunity being brought into play the curative effect that significant treatment antibacterial (streptococcus pneumoniae, escherichia coli, bacillus pyocyaneus, Bacillus proteus etc.) and virus (influenza virus, herpes simplex virus, myocarditis virus and mengo virus etc.) infect.
Summary of the invention
In order to overcome the above-mentioned deficiency of prior art, it is simple to the invention provides a kind of composition, safe, tilmicosin compound preparation easy to use and human body immunity improving power greatly.The present invention also provides the preparation method and the application of this tilmicosin compound preparation.
The present invention is achieved in that a kind of tilmicosin compound preparation, comprises following component: tilmicosin and pidotimod.
Tilmicosin and pidotimod all have clear and definite chemical constitution, can guarantee the effective dose of single composition in the compound preparation; And their pharmacological action shows synergy, and tilmicosin has antibiotic, antivirus action simultaneously, can directly suppress pathogenic growth; Pidotimod then has recovery and corrects the low state of anti-infectious immunity level, and both all have the active effect of the pulmonary alveolar macrophage of promotion; In addition, the safety of tilmicosin and pidotimod is good, and is less to liver function influence; Through inventor's experimental verification, make compound preparation and can not produce untoward reaction; Also have, tilmicosin all has oral effective, the equal mutually characteristics of usage with pidotimod.Tilmicosin is the special-purpose antibiotic of poultry, and embryo and piglets growth promoter are not had any harmful effect, and pidotimod is oral to be absorbed, and safety is good, does not see the untoward reaction report.The synergism of tilmicosin and pidotimod makes tilmicosin can be issued to the effect of better human body immunity improving power in the situation of lower use amount, thereby reduces cost.
Preferably, the mass ratio of described tilmicosin and pidotimod between 0.1 to 10, i.e. W
Tilmicosin: W
Pidotimod=0.1-10.
Preferred, the mass ratio of described tilmicosin and pidotimod between 0.5 to 3, i.e. W
Tilmicosin: W
Pidotimod=0.5-3, synergy the best of tilmicosin and pidotimod in this scope.
Preferably, described tilmicosin compound preparation also comprises at least a in sweeting agent, Sargassum powder, starch and the Testa Tritici.Because tilmicosin has bitterness, the adding of sweeting agent can improve the palatability of tilmicosin compound preparation, thereby helps the absorption of tilmicosin compound preparation; Sargassum powder has Thallus Laminariae (Thallus Eckloniae) fragrance, and the tilmicosin compound preparation that contains Sargassum powder can improve the appetite of sow, and promotes the sow lactogenic; Starch and Testa Tritici all also have more crude fibre, can reduce the appearance of prevention of sow constipation situation.
Preferred, described sweeting agent comprises at least a in arabinose, aspartame, stevioside, maltose alcohol, sucralose, Momordica-Glycosides, lactose and the anhydrous glucose.
Preferred, described tilmicosin compound preparation by mass percentage, comprises following component:
Tilmicosin 5 to 20%;
Pidotimod 10 to 30%;
Sweeting agent 10 to 20%;
Sargassum powder 30 to 75%.
Described sweeting agent comprises at least a in arabinose, aspartame, stevioside, maltose alcohol, sucralose, Momordica-Glycosides, lactose and the anhydrous glucose.
Preferred, the mass ratio of described sweeting agent and tilmicosin between 1 to 3, i.e. W
Sweeting agent: W
Tilmicosin=1-3, thus the bitterness of tilmicosin can be covered fully.
Preferred, the mass ratio between tilmicosin and the pidotimod between 0.5 to 3, i.e. W
Tilmicosin: W
Pidotimod=0.5-3, synergy the best of tilmicosin and pidotimod in this scope.
The present invention also provides a kind of method for preparing above-mentioned any tilmicosin compound preparation, and mixing is promptly in proportion for each component that is about to described tilmicosin compound preparation.
Preferably, concrete steps are sieved after preliminary the mixing for taking by weighing described each component of tilmicosin compound preparation in proportion, put into the two dimensional motion mixer then and further mix 20 to 40 minutes, and packing promptly.The granule of each component after sieving is more tiny, helps mixing.
In addition, the present invention also provides above-mentioned any the application of tilmicosin compound preparation in pregnancy period or sow in lactation are cultured.Mode by the sow health care, described tilmicosin compound preparation can suppress the intravital reproductive and respiratory syndrome virus content of sow, thereby reduce the band poison amount of reproductive and respiratory syndrome virus in the nascent piglets body, improve the immunity of organisms of sow and suckling piglets, effectively improve the every index of piglets fertility performance, produce better economic benefits.
After sow infects reproductive and respiratory syndrome virus, mainly show as in-pig stillborn fetus, miscarriage, mummy tire, weak son clinically, piglet respiratory symptom, multiple organ dysfunction syndrome and high mortality, the sow symptoms such as postponement of oestrusing again, and the phenomenon of immuning failure often has generation.And delivery room piglets Abwehrkraft des Koepers is low, infected easilier by parent, cause easier secondary of infected piglets and concurrent various virus, antibacterial, parasitic disease, often cause multiple eqpidemic disease such as swine fever, circovirus type II, colibacillosis to mix or secondary infection, cause the large quantities of death of piglets, pig industry is caused the remarkable economical loss.At present,, gavage some medicines usually for the suckling piglets, as tilmicosin etc. in order to improve suckling piglets Abwehrkraft des Koepers; But it is also longer that the suckling piglets gavages large usage quantity, course of treatment of tilmicosin at every turn, and need gavage separately, very inconvenient in actual production, and caused certain difficulty to feeding and management.
Compared with prior art, the invention has the beneficial effects as follows: tilmicosin compound preparation composition provided by the invention is simple, safe, and synergism can take place in tilmicosin in the compound preparation and pidotimod in body, make that tilmicosin can be under lower working concentration, by suppressing the intravital reproductive and respiratory syndrome virus content of sow, reduce the band poison amount of reproductive and respiratory syndrome virus in the nascent piglets body, improve the piglets immunity of organisms simultaneously, improve every index of piglets fertility performance, the raising culture benefit reduces cost.Tilmicosin compound preparation provided by the invention can be used for the breed of pregnancy period or sow in lactation.In addition, preparation method provided by the invention is simple, and the tilmicosin compound preparation of gained is stable.
The specific embodiment
Below in conjunction with specific embodiment the present invention is described in further detail.
One, raw material sources.
Used all ingredients all can be bought from the market among the embodiment, has listed the source of part reagent below:
Tilmicosin: content 〉=85%, available from Qilu Synva Pharmaceutical Co., Ltd.;
Pidotimod: content 〉=99%, available from Qilu Synva Pharmaceutical Co., Ltd.;
Arabinose: content 〉=99.99%, available from Beijing Yi Xinghong space economy and trade company limited;
Aspartame: content 〉=99%, available from the sensible food trade company limited of Beijing grand plan;
Stevioside: content 〉=99.87%, available from the grand food additive company limited of Beijing Yi Ze;
Maltose alcohol: content 〉=98%, available from Zhengzhou great power chemical industry company limited;
Sucralose: content 〉=99%, available from sea, Zibo billows chemical industry company limited;
Momordica-Glycosides: content 〉=80%, available from Shaanxi Sen Fu Bioisystech Co., Ltd;
Lactose: content 〉=98%, available from Shaanxi Sen Fu Bioisystech Co., Ltd;
Anhydrous glucose: content 〉=99%, available from Shaanxi Sen Fu Bioisystech Co., Ltd;
Sargassum powder: content is greater than 85%, available from the agricultural biochemical technology company limited of Shanghai benefit.
Table 1 is each components contents among the tilmicosin compound preparation embodiment 1 to 11.
Two, preparation method.
1. the preparation method of embodiment 1 in the table 1.
Take by weighing tilmicosin raw material 58.8g, pidotimod raw material 41.2g, mixing promptly gets the tilmicosin compound preparation.
2. the preparation method of embodiment 8 in the table 1.
According to each raw material of proportion requirement weighing of embodiment in the table 18, after preliminary the mixing, cross 24 mesh sieves, to put into the two dimensional motion mixer then and further mixed 20 to 40 minutes, packing is promptly.
Embodiment 2 to 7,9,10,11 all can be with reference to above-mentioned 2 kinds of methods preparation in the table 1.
Three, tilmicosin compound preparation clinical trial.
654 of in-pigs are divided into totally 6 groups of A, B, C, D, E, F at random, test 109 of sows for every group.Except that the feedstuff difference of throwing something and feeding, other conditions are all identical between 6 groups; The basis of 6 kinds of feedstuffs is identical, is sow feed commonly used, and difference is whether to add the difference of medicine and interpolation medicine.
The A group, the blank group; A organizes feedstuff: do not add any medicine.
The B group, the tilmicosin matched group; B organizes feedstuff: add tilmicosin, the tilmicosin final concentration is the 60g/ ton;
The C group, the pidotimod matched group; C organizes feedstuff: add pidotimod, the pidotimod final concentration is the 30g/ ton;
The D group, experimental group 1; D organizes feedstuff: add embodiment 8 described tilmicosin compound preparations, tilmicosin compound preparation final concentration is the 300g/ ton, and promptly the final concentration of tilmicosin is the 60g/ ton.
The E group, experimental group 2; E organizes feedstuff: add embodiment 7 described tilmicosin compound preparations, tilmicosin compound preparation final concentration is the 600g/ ton, and promptly the final concentration of tilmicosin is the 60g/ ton.
The F group, experimental group 3; F organizes feedstuff: add embodiment 6 described tilmicosin compound preparations, tilmicosin compound preparation final concentration is the 1200g/ ton, and promptly the final concentration of tilmicosin is the 60g/ ton.
Each was organized sow and all entered the delivery room preceding 7 days of expected date of confinement, uses corresponding forage feed then respectively, until piglets birth 21 days.
Investigate index: the unusual production incidence rate of sow (%), produce the on average strong young number (head) of strong young number (head), every nest, weak young incidence rate (%), stillborn fetus incidence rate (%), mummy incidence rate (%), nascent average weight (kg), wean average weight (kg), on average small weaning pig number (head), daily gain (g), the breeding rate of oestrusing in 7 days (%), the average feed intake of sow (kg/ days), the immune qualification rate (%) of reproductive and respiratory syndrome.
Experimental result sees Table 2.
Above-mentioned experimental result shows:
(1) weak young incidence rate: experimental group 1,2,3 is all low than matched group, tilmicosin group and pidotimod group, significant difference (p＜0.05);
(2) stillborn fetus incidence rate: experimental group 1,2,3 is all low than matched group, tilmicosin group and pidotimod group, significant difference (p＜0.05);
(3) nascent average weight: experimental group 1,2,3 is all than matched group, tilmicosin group and pidotimod group height, significant difference (p＜0.05);
(4) reproductive and respiratory syndrome immunity qualification rate: experimental group 1,2,3 is all obviously than matched group, tilmicosin group and pidotimod group height;
(5) wean average weight: experimental group 1,2,3 is all than matched group, tilmicosin group and pidotimod group height, significant difference (p＜0.05);
(6) palatability, the i.e. average feed intake of sow: experimental group 1,2,3 is all than matched group, tilmicosin group and pidotimod group height;
(7) average small weaning pig number: experimental group 1,2,3 is all than matched group, tilmicosin group and pidotimod group height, significant difference (p＜0.05).
Carry out same experiment with other embodiment in the table 1, the basically identical as a result of experimental result and the foregoing description does not repeat them here.
To sum up, the tilmicosin compound preparation is in every investigation index, as improves in the son a little less than the piglet, stillborn fetus, mummy tire, birth weight, weanling weight, sow 7 days aspect such as normal breeding rate than using tilmicosin or pidotimod that very remarkable advantages is arranged separately; Generally speaking, because the tilmicosin compound preparation mainly acts on the reproductive and respiratory syndrome influence factor and adjusts in the immunity, therefore can improve to a great extent by the sow body condition problem relevant with health level, comprise stress the back feed intake recovery (heat stress, vaccine stress), and reduce weak young, improve nascent body weight, improve weanling weight, avoid the remarkable improvement of aspects such as reproductive and respiratory syndrome immuning failure, when reducing aquaculture cost, improve culture benefit.
In addition, use because separately tilmicosin is sneaked in the feedstuff, its concentration should just can reach the effect of obvious raising sow immunity of organisms more than 400g/ ton feedstuff; And present tilmicosin raw material (content 〉=85%): the about 650 yuan/kg in market price, calculate according to 400g tilmicosin feedstuff per ton, cost is 305.9 yuan of/ton feedstuffs.
At present, pidotimod raw material (content 〉=99%): the about 2400 yuan/kg in market price.
Therefore the cost of experimental group D, E, F is respectively 118.6 yuan/ton, 264 yuan/ton, 336.7 yuan/ton.D group and E group have all significantly reduced cost, and F forms this with similar before, but take all factors into consideration the situation of aspects such as the weak son of piglet, stillborn fetus, mummy tire, birth weight, weanling weight, and the benefit of F group is still used tilmicosin (400g/ ton) height more separately.In sum, experimental group 1(embodiment 8) be most preferred tilmicosin compound preparation.
Above content be in conjunction with concrete preferred implementation to further describing that the present invention did, can not assert that concrete enforcement of the present invention is confined to these explanations.For the general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, can also make some simple deduction or replace, all should be considered as belonging to protection scope of the present invention.
Claims (10)
1. a tilmicosin compound preparation is characterized in that: comprise following component: tilmicosin and pidotimod.
2. a kind of tilmicosin compound preparation according to claim 1, it is characterized in that: the mass ratio of tilmicosin and pidotimod is between 0.1 to 10.
3. a kind of tilmicosin compound preparation according to claim 1 is characterized in that: also comprise at least a in sweeting agent, Sargassum powder, starch and the Testa Tritici.
4. a kind of tilmicosin compound preparation according to claim 3 is characterized in that: described sweeting agent comprises at least a in arabinose, aspartame, stevioside, maltose alcohol, sucralose, Momordica-Glycosides, lactose and the anhydrous glucose.
5. according to arbitrary described a kind of tilmicosin compound preparation in the claim 3, it is characterized in that: by mass percentage, comprising:
Tilmicosin 5 to 20%;
Pidotimod 10 to 30%;
Sweeting agent 10 to 30%;
Sargassum powder 30 to 75%.
6. a kind of tilmicosin compound preparation according to claim 5, it is characterized in that: the mass ratio of tilmicosin and pidotimod is between 0.5 to 3.
7. a kind of tilmicosin compound preparation according to claim 5, it is characterized in that: the mass ratio of sweeting agent and tilmicosin is between 1 to 3.
8. preparation method as arbitrary described tilmicosin compound preparation in the claim 1 to 7 is characterized in that: mixing is promptly in proportion with each component of described tilmicosin compound preparation.
9. the preparation method of a tilmicosin compound preparation as claimed in claim 8, it is characterized in that: take by weighing described each component of tilmicosin compound preparation in proportion, sieve after preliminary the mixing, put into the two dimensional motion mixer then and further mixed 20 to 40 minutes, packing promptly.
10. the application of arbitrary described tilmicosin compound preparation in pregnancy period or sow in lactation breed in the claim 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100663792A CN102172358B (en) | 2011-03-18 | 2011-03-18 | Timicosin compound preparation and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100663792A CN102172358B (en) | 2011-03-18 | 2011-03-18 | Timicosin compound preparation and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102172358A true CN102172358A (en) | 2011-09-07 |
| CN102172358B CN102172358B (en) | 2012-04-18 |
Family
ID=44515734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100663792A Active CN102172358B (en) | 2011-03-18 | 2011-03-18 | Timicosin compound preparation and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102172358B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006892A (en) * | 2012-12-28 | 2013-04-03 | 北京大北农动物保健科技有限责任公司 | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition |
| CN103182067A (en) * | 2011-12-30 | 2013-07-03 | 齐鲁动物保健品有限公司 | Application of pidotimod as immune enhancer on livestock and poultry |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623499A (en) * | 2008-07-07 | 2010-01-13 | 杨喜鸿 | Medical composition of antibiotic and pidotimod as well as preparation method and medical application thereof |
-
2011
- 2011-03-18 CN CN2011100663792A patent/CN102172358B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623499A (en) * | 2008-07-07 | 2010-01-13 | 杨喜鸿 | Medical composition of antibiotic and pidotimod as well as preparation method and medical application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103182067A (en) * | 2011-12-30 | 2013-07-03 | 齐鲁动物保健品有限公司 | Application of pidotimod as immune enhancer on livestock and poultry |
| CN103006892A (en) * | 2012-12-28 | 2013-04-03 | 北京大北农动物保健科技有限责任公司 | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition |
| CN103006892B (en) * | 2012-12-28 | 2018-01-02 | 北京大北农动物保健科技有限责任公司 | For preventing and treating pharmaceutical composition, premix and the batch of porcine viral diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102172358B (en) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101999558B (en) | Compound premix for pigs at different physiological stages | |
| CN101669587B (en) | Boar nutrition replenisher and preparation method thereof | |
| CN105395676B (en) | A kind of compound medicament composition for treating animal mycotoxicosis | |
| CN102038114B (en) | Concentrated feed for barren sows | |
| CN103504137A (en) | Enteric coated fodder acidifying agent and preparation method thereof | |
| CN104256070A (en) | Sow mating feed and using method thereof | |
| CN102178112A (en) | Premix feed for relieving astriction of sows | |
| CN105941870A (en) | Nanometer montmorillonite feed additive compound for detoxifying and diarrhea prevention of livestock and poultry | |
| CN106360018A (en) | Pig premix feed and pig compound feed | |
| KR20000024525A (en) | Functional Feed Additives and Method for Preparing The Same | |
| CN101422500B (en) | Immunoenhancement regulator of pig blue-ear disease vaccine and use thereof | |
| ES2948678T3 (en) | Use of nitrate for the treatment of postpartum dysgalactia syndrome of monogastric mammals | |
| CN102697787A (en) | Application of ponazuril to prevention and treatment of coccidiosis | |
| CN102232476B (en) | Ion physiological regulator for animals and preparation method thereof | |
| CN102172358B (en) | Timicosin compound preparation and preparation method and use thereof | |
| CN103750052A (en) | Sow feed additive for promoting growth and health of weaning pigs | |
| CN101715893B (en) | Pure natural piglet immunological enhancement feed additive and application thereof | |
| CN103271931A (en) | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof | |
| CN104824377B (en) | One broad sow anti-heat stress promotees breeding compound additive | |
| CN103892048B (en) | Piglet is calmed the nerves to increase and exempts from growth-promoting feedstuff additive, preparation method and application thereof | |
| CN108740443B (en) | Detoxification mold-removing agent for conditioning gastrointestinal tract function of sows and preparation method thereof | |
| CN101744157A (en) | Dairy cattle forage | |
| CN105661039A (en) | Breeding sow feed additives and preparation method thereof | |
| CN104920809A (en) | Feed additive premixing agent for improving sow milk and application method thereof | |
| CN105941908A (en) | Concentrated feed for conservation of piglets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 510642 next to building 9 in Wushan South China Agricultural University, Tianhe District, Guangzhou, Guangdong Province Patentee after: Guangdong Huanong Gaoke biopharmaceutical Co.,Ltd. Address before: 510642 west gate veterinary science and technology building, South China Agricultural University, Wushan, Tianhe District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU SCAU EXPERIMENTAL VETERINARY MEDICINE Co.,Ltd. |
|
| CP03 | Change of name, title or address |